EGFR and breast cancer: Previous studies suggest that cotargeting of PYK2 and EGFR could be beneficial for basal‐like patients with high EGFR levels,[16] and other studies suggest that immunosuppressive activity of TAMs is associated with upregulation of PD‐L1 and immune escape in TNBC.[15] Our finding that PYK2 inhibition reduced the number of TAMs and their pro‐tumorigenic phenotype suggests that PYK2 inhibition may sensitize BC to anti‐PDL1 blockade.